The Life Sciences team advised HotSpot Therapeutics on the completion of its $45 million Series A financing. The financing round will help advance SpotFinderTM, a specialized technology platform that enables HotSpot Therapeutics to identify, validate, and design novel chemistries targeting “regulatory hotspots” – a unique family of allosteric sites used by nature to regulate protein function. The financing was co-led by founding investors Atlas Venture and Sofinnova Partners.
HotSpot Therapeutics is a biotechnology company targeting nature’s regulatory mechanisms to create allosteric medicines that exhibit high precision and potency.
For additional details on the financing, please read the press release.